Cystic Fibrosis in Adults: Current and Future Management Strategies

In this: publication
By this: publisher
In this Subject: <a title="Allergy & Immunology" href="/content/subcat?j_subject=197&j_availability=">Allergy & Immunology
By this author: Brian M. Morrissey ;&nbsp; Bettina C. Schock ;&nbsp; Gregory P. Marelich ;&nbsp; Carroll E. Cross

Authors: Brian M. Morrissey; Bettina C. Schock; Gregory P. Marelich; Carroll E. Cross

Source: Clinical Reviews in Allergy and Immunology, Volume 25, Number 3, December 2003 , pp. 275-288(14)

Buy & download fulltext article:

Price: $42.00 plus tax (Refund Policy)

Abstract:

Over 30,000 individuals in the United States of America are living with cystic fibrosis (CF). Despite incremental advances in care and understanding of its pathophysiology, CF remains a significantly life-limiting disease. Readily accessible newborn screening, genetic testing, and an improved awareness have increased the early recognition of CF, atypical presentations of CF, and the CF-related diseases. Improvements in medical management have led to continually improving life expectancy for patients with CF. Despite improved management strategies, severe lung disease remains the commonly life-limiting pathology. We review the pathophysiology, diagnosis, and management of the respiratory-tract manifestations of CF that represent the life-limiting aspects of the condition and summarize upcoming and possible future therapies for patients with CF.

Keywords: Cystic fibrosis; CF; adult; CFTR

Document Type: Miscellaneous

Publication date: 2003-12-01